Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: Results from a Phase II, randomized, doubleblind, placebo-controlled trial

Authors
Category Primary study
JournalJournal of Clinical and Aesthetic Dermatology
Year 2021
This article has no abstract
Epistemonikos ID: 25206b177825c89893591f40e9209a118f8d000a
First added on: Feb 12, 2025